Category: Medical

Disability Health Japan Medical

Kissei Pharmaceutical advises “refrain from use” after 20 deaths after using vasculitis drug

Kissei Pharmaceutical Co., Ltd. announced that for its vasculitis treatment drug “Tavneos” (generic name: avacopan), 20 deaths have been reported in Japan among patients who took the medication. This figure includes cases where a causal relationship is unclear. On the 15th, the company called on healthcare professionals to refrain from administering the drug to new patients.

Disability Health Infectious Diseases Japan Medical

Risk of Hantavirus Spread in Japan Low: Health Ministry

The risk of hantavirus spreading in Japan through person-to-person transmission is low, even if infected passengers from a cruise ship linked to a recent outbreak enter the country, the health ministry said Wednesday. The ministry called on the public to remain calm, after three people died in a suspected hantavirus outbreak on the cruise ship in the Atlantic Ocean. A Japanese national is among passengers on the ship.

Abuse Crime Disability Intellectual disabilities Japan Medical

Male Radiologist Found Guilty of Molesting Fukuoka Female Student with Intellectual Disabilities During Medical Exam

In a retrial at the Fukuoka District Court on the 20th, Presiding Judge Shinichi Suzushima sentenced a 44-year-old male radiological technologist to one year and six months in prison, suspended for three years.The man had been charged with quasi-forcible indecency for touching the chest of a female student with intellectual disabilities during a 2018 medical check-up at a high school in Fukuoka Prefecture. Judge Suzushima upheld the credibility of the student’s testimony, describing the act as a “despicable crime that exploited his professional position.”

Disability iPS Japan Medical

Japan Eyes Public Insurance for iPS Cell-Based Products

Japan’s Central Social Insurance Medical Council on Wednesday started to discuss extending the public health insurance coverage to two regenerative medicine products using induced pluripotent stem, or iPS, cells. The council, which advises the health minister, is expected to decide the official prices for the products as early as summer. The products will come into use for medical treatment after that.